Mulubwa, MwilaMugabo, Pierre2023-03-072023-03-072019Mulubwa, M., & Mugabo, P. (2019). Amount of cycloserine emanating from terizidone metabolism and relationship with hepatic function in patients with drug resistant Tuberculosis. Drugs in R&D, 19 (3) , 289-296. https://doi.org/10.1007/s40268-019-00281-41179-6901https://doi.org/10.1007/s40268-019-00281-4http://hdl.handle.net/10566/8547The dosing of cycloserine and terizidone is the same, as both drugs are considered equivalent or used interchangeably. Nevertheless, it is not certain from the literature that these drugs are interchangeable. Therefore, the amount of cycloserine resulting from the metabolism of terizidone and the relationship with hepatic function were determined. This prospective clinical study involved 39 patients with drug-resistant tuberculosis admitted for an intensive phase of treatment. Cycloserine pharmacokinetic parameters for individual patients, like area under the curve (AUC), clearance (CLm/F), peak concentration (Cmax) and trough concentration (Cmin), were calculated from a previously validated joint population pharmacokinetic model of terizidone and cycloserine. Correlation and regression analyses were performed for pharmacokinetic parameters and unconjugated bilirubin (UB), conjugated bilirubin (CB), albumin, the ratio of aspartate transaminase to alanine aminotransferase (AST/ALT), or binding afnity of UB to albumin (Kaf), using R statistical software version 3.5.3.enPublic healthTuberculosisPatientsDrugsPharmacyArticle